Premium
P3–270: A 24‐week, open‐label extension to the ACTivities of daily living and cognitION (ACTION) study: Long‐term safety, tolerability and efficacy of a 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease
Author(s) -
Farlow Martin,
Grossberg George,
Sadowsky Carl,
Meng Xiangyi,
Somogyi Monique
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.1344
Subject(s) - tolerability , discontinuation , adverse effect , medicine , rivastigmine , activities of daily living , clinical global impression , demographics , double blind , dementia , physical therapy , disease , placebo , alternative medicine , demography , pathology , sociology , donepezil
Methods: Six hundred fifty six patients with dementia and mild cognitive impairment were recommended medical treatment and cognitive intervention programs through Seongdong-gu center for dementia. The Korean version of Mini-mental status examination (K-MMSE) and CERAD-K were done to evaluate cognitive improvement within12 months. Totally 52 patients were actively participated in cognitive intervention program. Comparison between active participants and pharmacotherapy treated only groups were done by using K-MMSE and CERAD-K. Results: There was significant cognitive improvement in the group of medical and cognitive intervention group in K-MMSE test through regional center for dementia (annual change of MMSE: 0.26). Frontal executive function and word memory recognition test were maintained and improved in active participants. Conclusions: Active cognitive intervention and multi-divisional programs might affect the cognitive improvement to the progression of dementia. These results might reflect the effectiveness of a variety of the interventional program through the regional center for dementia to the prevention of the dementia.